Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemia · Advanced Hematologic Malignancy · FHTX

Foghorn Therapeutics

Foghorn Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Watertown, USA HQ
2016 Founded
124 Employees
Public company Type
FHTX · NYSE Ticker
Company details
Status
Public
HQ
Watertown, USA
Founded
2016
Employees
124
Programs
5
Drugs
2
Patents
14
Intelligence · Clinical Programs

Foghorn Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Foghorn Therapeutics.

Foghorn Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Decitabine

    Foghorn Therapeutics

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial
  2. FHD-286

    Foghorn Therapeutics

    Advanced Hematologic Malignancy

    phase 1 small molecule active

    1 trial
  3. FHD-286

    Foghorn Therapeutics

    Metastatic Uveal Melanoma

    phase 1 small molecule terminated

    1 trial
  4. FHD-609

    Foghorn Therapeutics

    Advanced Synovial Sarcoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Foghorn Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.